Jefferies provides research and execution services in equity, fixed income, and foreign exchange markets.
Business Model:
Revenue: $6B
Employees: 5,001-10,000
Jefferies was acquired by
Jefferies Financial Group.
The acquisition happend on 2012-11-12.
Details of the transaction were not public
Address: 520 Madison Ave
City: New York
State: NY
Zip: 10022
Country: US
Jefferies provides research and execution services in equity, fixed income, and foreign exchange markets. Jefferies, a major global securities and investment banking group, has served companies and their investors for nearly 50 years and operates in more than 25 cities around the world. They provide world-class investment banking, sales and trading, research and asset management to a diverse range of corporate clients, institutional investors and high net worth individuals. They are industry experts, specializing in aerospace and defense, consumer energy, financial services, gaming and leisure, healthcare, industrials, maritime, media, real estate &a; lodging, technology, and telecommunications, with a dedicated private equity coverage group.
Contact Phone:
+12122842300
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2021 | Entrinsic Bioscience | Debt Financing | 49M |
1/2018 | Visible Alpha | Venture Round | 38M |
10/2018 | Petal | Debt Financing | 34M |
5/2019 | Figure | Debt Financing | 0 |
10/2017 | Abeona Therapeutics | Post-IPO Equity | 0 |
8/2016 | Advaxis | Post-IPO Equity | 0 |
1/2000 | Enterworks Acquisition Inc. | Venture Round | 25M |
10/2018 | Ualá | Series B | 0 |
6/2014 | Ablynx | Post-IPO Equity | 0 |
4/2018 | CloudMargin | Venture Round | 10M |
7/2022 | Illuminate Financial | Venture Round | - |
2/2022 | Superpedestrian | Series C | 0 |
3/2022 | NextRNA Therapeutics | Series A | 0 |
10/2014 | Symphony Communication Services | Series A | 66M |
3/2016 | Liminal BioSciences | Post-IPO Debt | 30M |
3/2000 | THINQ Learning Solutions | Series C | 0 |
7/2014 | Aura Financial | Series B | 0 |
3/2011 | BONDS.COM | Venture Round | 0 |
2/2017 | Bond Street | Debt Financing | 300M |
1/2019 | dv01 | Series B | 15M |
6/2016 | dv01 | Convertible Note | 5M |
5/2015 | Affirm | Series B | 275M |
4/2015 | Avant | Debt Financing | 400M |
2/2018 | Ualá | Series A | 10M |
4/2016 | Affirm | Series D | 100M |
1/2017 | Ualá | Seed Round | - |
9/2017 | Ualá | Convertible Note | - |
2/2022 | Superpedestrian | Debt Financing | - |
6/2015 | Bond Street | Series A | 10M |
8/2014 | Avant | Debt Financing | 200M |
6/2015 | Bond Street | Debt Financing | 100M |
3/2000 | 1800wedding.com | Series C | 10.4M |
9/2019 | Petal | Debt | 300M |
7/2022 | Illuminate Financial | Venture Round | - |
3/2022 | NextRNA Therapeutics | Series A | 0 |
2/2022 | Superpedestrian | Debt Financing | - |
2/2022 | Superpedestrian | Series C | 0 |
6/2021 | Entrinsic Bioscience | Debt Financing | 0 |
9/2019 | Petal | Debt Financing | 0 |
5/2019 | Figure | Debt Financing | 0 |
1/2019 | dv01 | Series B | 0 |
10/2018 | Ualá | Series B | 0 |
10/2018 | Petal | Debt Financing | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|